RS56810B1 - Indolkarbonitrili kao selektivni modulatori androgen receptora - Google Patents
Indolkarbonitrili kao selektivni modulatori androgen receptoraInfo
- Publication number
- RS56810B1 RS56810B1 RS20180119A RSP20180119A RS56810B1 RS 56810 B1 RS56810 B1 RS 56810B1 RS 20180119 A RS20180119 A RS 20180119A RS P20180119 A RSP20180119 A RS P20180119A RS 56810 B1 RS56810 B1 RS 56810B1
- Authority
- RS
- Serbia
- Prior art keywords
- indolecarbonitriles
- androgen receptor
- receptor modulators
- selective androgen
- selective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261672455P | 2012-07-17 | 2012-07-17 | |
US201361748874P | 2013-01-04 | 2013-01-04 | |
PCT/IB2013/001530 WO2014013309A1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
EP13758975.0A EP2875013B1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
RS56810B1 true RS56810B1 (sr) | 2018-04-30 |
Family
ID=49117887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20180119A RS56810B1 (sr) | 2012-07-17 | 2013-07-15 | Indolkarbonitrili kao selektivni modulatori androgen receptora |
Country Status (39)
Country | Link |
---|---|
US (5) | US8957104B2 (sr) |
EP (1) | EP2875013B1 (sr) |
JP (1) | JP6106746B2 (sr) |
KR (1) | KR102127939B1 (sr) |
CN (1) | CN104619693B (sr) |
AR (1) | AR091770A1 (sr) |
AU (1) | AU2013291721B2 (sr) |
BR (1) | BR112015000940B1 (sr) |
CA (1) | CA2879104C (sr) |
CL (1) | CL2015000119A1 (sr) |
CO (1) | CO7240378A2 (sr) |
CR (1) | CR20150008A (sr) |
CY (1) | CY1120064T1 (sr) |
DK (1) | DK2875013T3 (sr) |
DO (1) | DOP2015000004A (sr) |
EA (1) | EA026371B8 (sr) |
ES (1) | ES2657912T3 (sr) |
HK (1) | HK1208867A1 (sr) |
HR (1) | HRP20180061T1 (sr) |
HU (1) | HUE036238T2 (sr) |
IL (1) | IL236448A (sr) |
IN (1) | IN2014KN02993A (sr) |
JO (1) | JO3384B1 (sr) |
LT (1) | LT2875013T (sr) |
ME (1) | ME02996B (sr) |
MX (1) | MX349943B (sr) |
MY (2) | MY173845A (sr) |
NZ (1) | NZ703129A (sr) |
PE (1) | PE20150371A1 (sr) |
PH (1) | PH12015500104B1 (sr) |
PL (1) | PL2875013T3 (sr) |
PT (1) | PT2875013T (sr) |
RS (1) | RS56810B1 (sr) |
SG (1) | SG11201408493WA (sr) |
SI (1) | SI2875013T1 (sr) |
TW (1) | TWI574946B (sr) |
UY (1) | UY34911A (sr) |
WO (1) | WO2014013309A1 (sr) |
ZA (1) | ZA201500096B (sr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
JP6106746B2 (ja) | 2012-07-17 | 2017-04-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類 |
WO2015110958A1 (en) | 2014-01-21 | 2015-07-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile |
EP3206675A4 (en) * | 2014-10-16 | 2018-07-11 | GTx, Inc. | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs |
CN105130872B (zh) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | 一种3位三氟甲基取代吲哚的制备方法 |
CN110437125B (zh) * | 2019-09-06 | 2021-03-12 | 苏州旺山旺水生物医药有限公司 | 一种Tezacaftor中间体II的制备方法 |
WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
CN115010574B (zh) * | 2022-06-06 | 2024-01-05 | 爱斯特(成都)生物制药股份有限公司 | 1-溴-2-氯-4-氟-2碘苯的合成方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1056719A2 (en) | 1998-02-25 | 2000-12-06 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
ID26698A (id) * | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
US7235668B2 (en) | 2002-05-24 | 2007-06-26 | Bayer Cropscience Ag | Process for the preparation of thioalkylamine derivatives |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
CN1960973A (zh) * | 2004-03-30 | 2007-05-09 | 惠氏公司 | 作为去甲肾上腺素(ne)与血清素(5-h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1-(1h-吲哚-1-基)-3-(4-甲基哌嗪-1-基)-1-苯基丙烷-2-醇衍生物和相关化合物 |
ATE525354T1 (de) | 2004-05-03 | 2011-10-15 | Janssen Pharmaceutica Nv | Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms) |
US7427682B2 (en) | 2004-05-03 | 2008-09-23 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
EP1753749B1 (en) | 2004-05-03 | 2014-07-30 | Janssen Pharmaceutica NV | Novel indole derivatives as selective androgen receptor modulators (sarms) |
EP1756054B1 (en) * | 2004-06-01 | 2010-03-31 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
EP1913000B1 (en) * | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
CN101426778A (zh) * | 2006-03-15 | 2009-05-06 | 惠氏公司 | 作为组胺-3拮抗剂的n-经取代-氮杂环基胺 |
CA2645731A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
EP2079466B1 (en) * | 2006-09-29 | 2014-01-15 | GlaxoSmithKline LLC | Substituted indole compounds |
JP4884570B2 (ja) * | 2008-08-20 | 2012-02-29 | ファイザー・インク | ピロロ[2,3−d]ピリミジン化合物 |
WO2010118287A1 (en) * | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
IN2012DN02577A (sr) * | 2009-10-15 | 2015-08-28 | Pfizer | |
JP5739446B2 (ja) * | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ[2,3−d]ピリミジン化合物 |
DK2590647T3 (en) | 2010-07-07 | 2018-02-12 | Univ Texas | Pro-neurogenic compounds |
US8933113B2 (en) * | 2011-01-20 | 2015-01-13 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
PL2796460T3 (pl) * | 2011-12-21 | 2018-12-31 | Jiangsu Hengrui Medicine Co. Ltd. | Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne |
JP6106746B2 (ja) * | 2012-07-17 | 2017-04-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類 |
WO2015110958A1 (en) * | 2014-01-21 | 2015-07-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile |
-
2013
- 2013-07-15 JP JP2015522180A patent/JP6106746B2/ja active Active
- 2013-07-15 TW TW102125297A patent/TWI574946B/zh active
- 2013-07-15 MY MYPI2015000121A patent/MY173845A/en unknown
- 2013-07-15 MY MYPI2018001949A patent/MY198512A/en unknown
- 2013-07-15 PT PT137589750T patent/PT2875013T/pt unknown
- 2013-07-15 PL PL13758975T patent/PL2875013T3/pl unknown
- 2013-07-15 BR BR112015000940-9A patent/BR112015000940B1/pt active IP Right Grant
- 2013-07-15 KR KR1020157003959A patent/KR102127939B1/ko active IP Right Grant
- 2013-07-15 IN IN2993KON2014 patent/IN2014KN02993A/en unknown
- 2013-07-15 AR ARP130102513A patent/AR091770A1/es active IP Right Grant
- 2013-07-15 ME MEP-2018-16A patent/ME02996B/me unknown
- 2013-07-15 RS RS20180119A patent/RS56810B1/sr unknown
- 2013-07-15 CN CN201380048232.8A patent/CN104619693B/zh active Active
- 2013-07-15 EP EP13758975.0A patent/EP2875013B1/en active Active
- 2013-07-15 US US13/941,911 patent/US8957104B2/en active Active
- 2013-07-15 LT LTEP13758975.0T patent/LT2875013T/lt unknown
- 2013-07-15 AU AU2013291721A patent/AU2013291721B2/en active Active
- 2013-07-15 PE PE2015000039A patent/PE20150371A1/es active IP Right Grant
- 2013-07-15 HU HUE13758975A patent/HUE036238T2/hu unknown
- 2013-07-15 MX MX2015000825A patent/MX349943B/es active IP Right Grant
- 2013-07-15 DK DK13758975.0T patent/DK2875013T3/en active
- 2013-07-15 ES ES13758975.0T patent/ES2657912T3/es active Active
- 2013-07-15 SG SG11201408493WA patent/SG11201408493WA/en unknown
- 2013-07-15 WO PCT/IB2013/001530 patent/WO2014013309A1/en active Application Filing
- 2013-07-15 SI SI201330945T patent/SI2875013T1/en unknown
- 2013-07-15 NZ NZ703129A patent/NZ703129A/en unknown
- 2013-07-15 CA CA2879104A patent/CA2879104C/en active Active
- 2013-07-15 EA EA201492237A patent/EA026371B8/ru not_active IP Right Cessation
- 2013-07-15 UY UY0001034911A patent/UY34911A/es not_active Application Discontinuation
- 2013-07-15 JO JOP/2013/0214A patent/JO3384B1/ar active
-
2014
- 2014-11-20 US US14/549,034 patent/US9533948B2/en active Active
- 2014-12-23 CO CO14282153A patent/CO7240378A2/es unknown
- 2014-12-25 IL IL236448A patent/IL236448A/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00096A patent/ZA201500096B/en unknown
- 2015-01-08 DO DO2015000004A patent/DOP2015000004A/es unknown
- 2015-01-09 CR CR20150008A patent/CR20150008A/es unknown
- 2015-01-14 PH PH12015500104A patent/PH12015500104B1/en unknown
- 2015-01-16 CL CL2015000119A patent/CL2015000119A1/es unknown
- 2015-09-30 HK HK15109640.8A patent/HK1208867A1/xx unknown
-
2016
- 2016-11-22 US US15/358,458 patent/US10196353B2/en active Active
-
2018
- 2018-01-15 HR HRP20180061TT patent/HRP20180061T1/hr unknown
- 2018-02-13 CY CY20181100173T patent/CY1120064T1/el unknown
- 2018-12-20 US US16/226,763 patent/US10710963B2/en active Active
-
2020
- 2020-05-12 US US16/872,949 patent/US11299457B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211039A1 (en) | Engineering -cell receptors | |
GB201213700D0 (en) | Receptor antagnists II | |
EP2531029A4 (en) | SELECTIVE ANDROGEN RECEPTOR MODULATORS | |
IL251897A0 (en) | X-receptor modulators of the liver | |
HK1208867A1 (en) | Indolecarbonitriles as selective androgen receptor modulators | |
HK1206333A1 (en) | Liver receptor modulators | |
HK1209744A1 (en) | Novel selective androgen receptor modulators | |
EP2825299A4 (en) | MIXING SYSTEM | |
IL231440A0 (en) | Selective androgen receptor modulators | |
PL2820010T3 (pl) | Pochodne benzofurano-2-sulfonamidu jako modulatory receptora chemokinowego | |
GB201223053D0 (en) | Receptor |